Kidney cancer research in 2014 was characterized by a diverse array of studies. Advances were made in both the localized and the metastatic renal cell carcinoma (RCC) arenas. Importantly, significant progress was also made in our understanding of the underpinnings of RCC tumorigenesis and progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tomaszewski, J. J., Smaldone, M. C., Uzzo, R. G. & Kutikov, A. Is radical nephrectomy a legitimate therapeutic option in patients with renal masses amenable to nephron-sparing surgery? BJU Int. http://dx.doi.org/10.1111/bju.12696 (2014).
Van Poppel, H. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59, 543–552 (2011).
Scosyrev, E., Messing, E. M., Sylvester, R., Campbell, S. & Van Poppel, H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur. Urol. 65, 372–377 (2014).
Demirjian, S. et al. Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival. J. Urol. 192, 1057–1063 (2014).
Motzer, R. J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 369, 722–731 (2013).
Motzer, R. J., Hutson, T. E., McCann, L., Deen, K. & Choueiri, T. K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N. Engl. J. Med. 370, 1769–1770 (2014).
Escudier, B. et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J. Clin. Oncol. 32, 1412–1418 (2014).
Sun, M., Larcher, A., Schiffmann, J. & Karakiewicz, P. I. PISCES: A horoscope for first-line targeted therapy of metastatic renal cell carcinoma. J. Clin. Oncol. 32, 3783 (2014).
Li, B. et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 513, 251–255 (2014).
Cancer Genome Atlas Research network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ito, T., Kutikov, A. Key advances promise progress for kidney cancer patients. Nat Rev Urol 12, 69–70 (2015). https://doi.org/10.1038/nrurol.2014.356
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.356
